Pontifax Management 4 G.P. (2015) Ltd. - 13 May 2021 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.

Reporting relationship: 10%+ Owner
Issuer ticker: ELOX on Nasdaq
Reported as of: 13 May 2021
Net transaction value: +$7,999,999
SEC form: 4
Accepted by SEC: 17 May 2021, 07:03:28 UTC
Prior SEC filing: 30 Nov 2022
Next SEC filing: 30 Nov 2022
Source filing: View source filing
Reporting owner signature: Pontifax Management 4 G.P. (2015) Ltd. /s/ Neil S. Belloff, Attorney-in-Fact on behalf of Tomer Kariv, Chief Executive Officer

Filing notes and source

Key filing fact

Pontifax Management 4 G.P. (2015) Ltd. filed Form 4 for Eloxx Pharmaceuticals, Inc. on 17 May 2021.

Key facts

This page summarizes Pontifax Management 4 G.P. (2015) Ltd.'s Form 4 filing for Eloxx Pharmaceuticals, Inc..
4 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 17 May 2021, 07:03.

Change

Previous filing in this sequence was filed on 30 Nov 2022.
Current net transaction value: +$7,999,999.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELOX transaction

Common Stock

Purchase

Transaction value: $1,728,842
Shares: +1,280,624
Change %: +251%
Price: $1.35
Shares after: 1,791,470
Date: 13 May 2021
Ownership: By Pontifax Investment Fund
Footnotes: F1, F2

ELOX transaction

Common Stock

Purchase

Transaction value: $3,551,157
Shares: +2,630,487
Change %: +251%
Price: $1.35
Shares after: 3,679,797
Date: 13 May 2021
Ownership: By Pontifax Investment Fund
Footnotes: F1, F3

ELOX transaction

Common Stock

Purchase

Transaction value: $1,920,000
Shares: +1,422,222
Change %: +251%
Price: $1.35
Shares after: 1,989,551
Date: 13 May 2021
Ownership: By Pontifax Investment Fund
Footnotes: F1, F4

ELOX transaction

Common Stock

Purchase

Transaction value: $799,999
Shares: +592,592
Change %: +2469%
Price: $1.35
Shares after: 616,592
Date: 13 May 2021
Ownership: By Pontifax Investment Fund
Footnotes: F1, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021.

Footnote F2

Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

Footnote F3

Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

Footnote F4

Represents shares of the Issuer held by Pontifax (China) IV L.P. ("China IV"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

Footnote F5

Represents shares of the Issuer held by Pontifax Late Stage Fund L.P.("Late Stage Fund"). Pontifax Late Stage GP Ltd. ("Late Stage GP"), the general partner of Late Stage Fund, has a Strategic Alliance Agreement with Pontifax IV. By virtue of this relationship, Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Late Stage Fund. Each of Management 4, Pontifax IV, Late Stage Fund and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.